|
Aug 9
|
Horizon Therapeutics plc - Rule 2.12 Announcement
|
|
Aug 8
|
Horizon Therapeutics plc Reports Second-Quarter 2023 Financial Results
|
|
Jun 28
|
The New M&A Rules That Would Delay Million-Dollar Deals
|
|
Jun 26
|
TEPEZZA® (teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED)
|
|
Jun 22
|
Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
|